The Science Behind SURYA-101
Understanding our lipid mediator approach for diabetic retinopathy
Why the retina is lipid-rich
The retina has one of the highest concentrations of lipids in the body, particularly docosahexaenoic acid (DHA) and arachidonic acid (AA). These lipids are essential for normal retinal function, including photoreceptor cell membrane structure and signaling. In diabetes, research suggests that AA and DHA levels may be reduced in both plasma and retinal tissue, potentially contributing to retinal dysfunction.
How LXA4 relates to inflammation signaling
Lipoxin A4 (LXA4) is a specialized pro-resolving lipid mediator derived from arachidonic acid. Unlike pro-inflammatory lipids, LXA4 helps resolve inflammation naturally. Research indicates that LXA4 may block NFkB (a key inflammation pathway), reduce IL-6 levels, and inhibit VEGF and angiopoietin-2. In diabetic retinopathy, LXA4 levels appear to be reduced, which may contribute to chronic, unresolved inflammation.
Where VEGF fits in abnormal vessel growth
VEGF (Vascular Endothelial Growth Factor) is a key driver of neovascularization—the abnormal blood vessel growth that characterizes proliferative diabetic retinopathy. These new vessels are fragile and prone to leaking or bleeding. Current anti-VEGF therapies work by binding to VEGF after it's produced. SURYA-101's investigational approach aims to reduce VEGF production itself, potentially addressing the problem further upstream.
Important Notice: The diagrams above are simplified educational illustrations. SURYA-101 is investigational and has not been proven to work as depicted. SURYA-101 is investigational and not approved by the FDA or any regulatory authority. It is not available as an approved treatment option.
Explore the DR Program
Learn more about how this science translates into our investigational approach for diabetic retinopathy.